Codice QR

Safety and Immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I First-in-Human Trial

BackgroundTransmission blocking vaccines targeting the sexual-stages of the malaria parasite could play a major role to achieve elimination and eradication of malaria. The Plasmodium falciparum Pfs25 protein (Pfs25) is the most clinically advanced candidate sexual-stage antigen. IMX313, a complement...

Descrizione completa

Salvato in:
Autori principali: Hans de Graaf, Ruth O. Payne, Iona Taylor, Kazutoyo Miura, Carol A. Long, Sean C. Elias, Marija Zaric, Angela M. Minassian, Sarah E. Silk, Lee Li, Ian D. Poulton, Megan Baker, Simon J. Draper, Diane Gbesemete, Nathan J. Brendish, Filipa Martins, Arianna Marini, David Mekhaiel, Nick J. Edwards, Rachel Roberts, Johan Vekemans, Sarah Moyle, Saul N. Faust, Eleanor Berrie, Alison M. Lawrie, Fergal Hill, Adrian V. S. Hill, Sumi Biswas
Natura: Artigo
Lingua:Inglês
Pubblicazione: Frontiers Media S.A. 2021-07-01
Serie:Frontiers in Immunology
Soggetti:
Pfs25
malaria
transmission-blocking
IMX313
vaccine
Accesso online:https://www.frontiersin.org/articles/10.3389/fimmu.2021.694759/full
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi